Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution...
Reexamination Certificate
2001-09-13
2003-07-01
Tate, Christopher R. (Department: 1651)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Reexamination Certificate
active
06586016
ABSTRACT:
FIELD OF INVENTION
This invention is in the field of medicinal prevention and treatment of cancers and infections. In particular, it relates to a Chinese herbal formulation, ST 188L, and a method for the prevention and treatment of cancers and infections that comprises administering an effective dose of the herbal formulation. The raw materials for such formulation are
Ecchinops grijissii, Cirsium segetum
Bge,
Solanum indicum
Linn,
Lonicerae flos
, and
Zizyphi fructus.
BACKGROUND OF INVENTION
Cancer is the second leading cause of death, next to cardiovascular disease, in the US. According to WHO, there are 31 million cancer sufferers worldwide, 10 million new cases, and 7 million die of it each year. The medical cost, care cost, and society cost are difficult to be estimated. Investigators continue to search for new therapeutic strategies for cancers.
The pathological and molecular mechanisms for cancer initiation and promotion have been revealed after decades of researches. There are many genes involved in the initiation and progression of cancers, some are oncogenic and some are tumor suppressive. Genetic, endocrinologic, immunologic, and environmental factors intertwine in the process of transformation and progression. Cancers are diseases caused by multi-factors under complex mechanisms.
The control and cure of cancers remain to be one of the most challenging health care tasks. Current modalities of therapies for cancers include surgery, radiotherapy, chemotherapy, gene therapy, immune therapy, or a combination of any of these treatments. Although surgery is the most effective way to eradicate tumor, when the patients are diagnosed with cancers, their tumors have substantially become inoperable. Current radiotherapy and chemotherapy modalities are unable to discriminate normal cells from neoplastic cells; therefore, there are apparent dose-limiting toxicities. Gene therapy is still at very early stage of clinical practice. Lately, immune therapy has shown very promising results.
Cancer cells are vulnerable to immune effector cells such as macrophages, natural killer cells (NK cells), and cytotoxic T lymphocytes (Vujanovic N L, Yasumura S, and Hirabayashi H., J. Immunol 1995; 154:281-9; Kuge S, Miura Y, Nakamura Y, Mitomi T, Habu S, and Nishimura T., J. Immunol 1995; 154:1777-85; and Nabioullin R, Sone S, Mizuno K:, J Leukocyte Biol 1994; 55:437-42. However, lymphocyte functions are suppressed in patients with cancer and in animal tumor models (Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A., Immunol Today 1997; 18:493-7; and Wojtowiczpraga S., J. Immunother 1997; 20:165-77.). A reduction in immune competence due to suppressor cells including inhibitory T cells, macrophages, and immature bone marrow nonspecific suppressive cells has been correlated with reduced survival of patients and animals with cancer (Kaffenbeerger W, Holzer-Muller L, Auberger T, Clasen B P, Hohlmeier G, and van Beuningen D., Strahlenther Onkol 1995; 171:444-53; Aoe T, Okamoto Y, and Saito T., J. Exp. Med. 1995; 181:1881-6; and Young M R I, Schmidt-Pak A, Wright M A, Matthews J P, Collins S L, and Petruzzelli G., Clin Cancer Res.1995; 1:95-103). The induction and enhancement of immune activity most likely would have impact on cancer therapy. Most of the cancer patients eventually die of tumor metastasis. Many evidences demonstrate that NK cells and cytokines produced by NK cells inhibited tumor metastasis (Smyth M J, et al., J. Immunol. 1999; 162: 6658-6662; Takeda K, et al., J. Immunol. 1996; 156: 3366-3373; and Siders W M, et al., J. Immunol. 1998; 160: 5465-33735474).
NK cells respond to and are important in defense against a number of different infectious agents, including viruses, bacteria, protozoa, and parasites (Biron C A., Curr. Opin. Immunol. 1997; 9(1): 24-34; Unanue E R., Curr. Opin. Immunol. 1997. 9: 35-43; Scharton-Kersten T M, and Sher A., Curr. Opin. Immunol. 1997. 9: 44-51; Scharton-Kersten T M, and Sher A., Curr. Opin. Immunol. 1997. 9: 44-51; and Scott P, and Trinchieri G., Curr. Opin. Immunol. 1995. 7: 34-40). There are not many effective drugs for some of the infectious agents, for example, viruses. The emergences of drug resistant variants are one of the most difficult tasks for health care worldwide. NK cells participate in innate immunity and early defense within several hours to days after primary infections, whereas adaptive T and B cell responses develop after more than one week. Virus, such as arenaviruses (Welsh R M., J. Exp. Med. 1978. 148: 163-181), herpes viruses (Ching C, and Lopez C., 1979. Infect. Immun. 26: 49-56), orthomyxoviruses (Santoli D, Trinchieri G, and Koprowski H., 1978. J. Immunol. 121: 532-538), and picornaviruses (Godeny E K, and Gauntt C J., 1986. J. Immunol. 137: 1695-1702) induced interferon &agr;/&bgr; enhance NK cell-mediated cytotoxicity. NK cells can produce antimicrobial and immunoregulatory cytokines, such as interferon &ggr; (Orange J S, and Biron C A., 1996. J. Immunol. 156: 4746-47; and Orange J S, Wang B, Terhorst C, and Biron C A., 1995. J. Exp. Med. 182: 1045-1056). Low NK cell cytotoxic activity was linked with increased sensitivity to severe disseminating herpes infection (Biron C A, Byron K S, and Sullivan J L., 1989. N. Engl. J. Med. 320: 1731-1735; and Joncas J, Monczak Y, Ghibu F, Alfieri C, Bonin A, Ahronheim G, and Rivard G., 1989. J. Med. Virol. 28:110-117). There is also evidence showed that IL-2 increased LAK activity preferentially against HBV transfected HepG2-2215 cells when compared with parental HepG2 cells (Tsang T, Se C J, Yu M, and Tang, S L., 1994. Chung Hwa Yi Hsueh Tsa Chih 74(4):235-237).
SUMMARY OF INVENTION
The present invention involves the preparation and use of a formulation, ST 188L, a Chinese herbal medicine, on preventing and treating cancers and infectious diseases.
One aspect of the invention is to provide for a pharmaceutical composition for preventing and treating cancers comprising a formulation prepared ratably from a group of herbal plants consisting essentially of
Ecchinops grijissii, Cirsium segetum
Bge,
Solanum indicum
Linn,
Lonicerae flos
, and
Zizyphi fructus
in a pharmaceutically acceptable carrier or diluent. The
Ecchinops grijissii, Cirsium segetum
Bge,
Solanum indicum
Linn,
Lonicerae flos
, and
Zizyphi fructus
are prepared in this pharmaceutical composition respectively at a ratio of 5-15:2-6:2-6:1-10:1-5, preferably, at a ratio of 5:2:2:1:1. The formulation can be prepared in many desirable medicine dosage forms such as a tablet, soft gel, granule, powder, liquid, capsule or honey ball.
One more aspect of the invention is to provide for a method of providing therapeutical benefits to a recipient for preventing and treating cancers, which comprises the steps of preparing a pharmaceutical composition selected from extracts of a group of herbal plants consisting essentially of
Ecchinops grijissii, Cirsium segetum
Bge,
Solanum indicum
Linn,
Lonicerae flos
, and
Zizyphi fructus
; formulating said extracts in a pharmaceutically acceptable carrier or diluent in an amount sufficient to provide the intended therapeutical benefits; and administering said pharmaceutical composition to said recipient. The pharmaceutical composition is preferably administered by an oral route in a variety of desirable medicine dosage forms including, but without limitation to, a tablet, soft gel, granule, powder, liquid, capsule or honey ball. The amount of the pharmaceutical composition sufficient to provide the intended benefits is at the range of 0.75 g/Kg/day to 1.5 g/Kg/day.
One more aspect of the invention is to provide for a method and a pharmaceutical composition, that comprises the same ST 188L formulation prepared ratably from
Ecchinops grijissii, Cirsium segetum
Bge,
Solanum indicum
Linn,
Lonicerae flos
, and
Zizyphi fructus
in a pharmaceutically acceptable carrier or diluent at a ratio of 5-15:2-6:2-6:1-10:1-5, for enhancing endogenous immune system of a recipient. Evidence shows that the recipient's endogenous immune system is enhanced due to the increase of n
Hwang Kou Mark
Liu Suying
Tsai Yi Ming
Chang Chi Ping
Pacific Law Group LLP
Patten Patricia
Sagittarius Life Science Corp.
Tate Christopher R.
LandOfFree
ST 188L as the prevention and treatment for cancers and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ST 188L as the prevention and treatment for cancers and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ST 188L as the prevention and treatment for cancers and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3010662